

Freedom of Information Act 2000 – Request Reference FoI/24/107
Migraine Treatment

A. How many patients have been treated with the following drugs in the past 4 months:

For the period 1 October 2023 to 31 January 2024:

- Atogepant (Aquipta) – 0
- Erenumab (Aimovig) – 23
- Eptinezumab (Vypti) – 2
- Fremanezumab (Ajovy) – 6
- Galcanezumab (Emgality) – 25
- Rimegepant (Vyatura) – 1
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – 81 (any disease)

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within Regulations for responding to a request. The UHB has therefore relied upon the section 12 exemption of the Freedom of Information Act 2000 ('Exemption where cost of compliance exceeds appropriate limit') and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within Regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the Fees Regulations for this amount of work (18 hours) is £450 for the UHB. The Fees Regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes, the UHB does tend to initiate a treatment pause at 12 months if the patient has had a sustained response to treatment, with an aim to restart should the patient fulfil the criteria.